{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:07:48Z","timestamp":1774382868396,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>The diagnostic value of tumor markers in pleural effusion (PE) and serum for malignant pleural effusion (MPE) is still in debate. This study aimed to evaluate the diagnostic value of six tumor markers in PE, serum, and the corresponding PE\/serum (PE\/S) ratio in distinguishing MPE from benign pleural effusion (BPE).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>A total of 1,230 patients with PE (452 MPEs and 778 BPEs) were retrospectively included in the study. PE and serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), cytokeratin 19 fragment (CYFRA 21-1), and neuron-specific enolase (NSE) were measured. The area under the curve (AUC) was used to assess the single and combined diagnostic values of the six tumor markers for MPE.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>The levels of the six tumor markers in PE, serum, and PE\/S were significantly higher in MPE than that in BPE, except for serum CA125. PE CEA showed the highest AUC [0.890 (0.871\u20130.907)] at a cut-off value of 3.7\u00a0ng\/ml compared to any single tumor marker using receiver operating characteristic (ROC) analysis. The specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) of PE CEA were 74.1%, 95.5%, 90.5%, 86.4%, 16.47, and 0.27, respectively. The combination of PE CEA and serum CYFRA21-1 showed the best diagnostic performance with an AUC of 0.934 (sensitivity, 79.9%; specificity, 95.7%, PPV, 90.5; PLR, 17.35) among all two or three combinations. Besides, serum CYFRA21-1 was the best diagnostic tumor marker in distinguishing cytology-negative MPE from BPE at a cut-off value of 3.0\u00a0ng\/ml.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>PE CEA was the best diagnostic tumor marker in distinguishing MPE from BPE. Serum CYFRA21-1 was the best diagnostic tumor marker in distinguishing cytology-negative MPE from BPE. The combination of PE CEA and serum CYFRA21-1 could increase the diagnostic performance in distinguishing MPE from BPE and cytology-negative MPE from BPE.<\/jats:p>","DOI":"10.3389\/pore.2022.1610280","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T04:11:34Z","timestamp":1650427894000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study"],"prefix":"10.3389","volume":"28","author":[{"given":"Xin","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of Malignant Pleural Effusions. An Official ATS\/STS\/STR Clinical Practice Guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.ebiom.2020.102924","article-title":"Development and Validation of a Novel Scoring System Developed from a Nomogram to Identify Malignant Pleural Effusion","volume":"58","author":"Wang","year":"2020","journal-title":"EBioMedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccm.2020.02.009","article-title":"Management of Malignant Pleural Effusions","volume":"41","author":"Shafiq","year":"2020","journal-title":"Clin Chest Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.arbres.2013.11.007","article-title":"Etiology of Pleural Effusions: Analysis of More Than 3,000 Consecutive Thoracenteses","volume":"50","author":"Porcel","year":"2014","journal-title":"Archivos de Bronconeumolog\u00eda (English Edition)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1801254","DOI":"10.1183\/13993003.01254-2018","article-title":"Investigating Unilateral Pleural Effusions: the Role of Cytology","volume":"52","author":"Arnold","year":"2018","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/lbr.0000000000000145","article-title":"Role of Medical Thoracoscopy and Closed-Blind Pleural Biopsy in Undiagnosed Exudative Pleural Effusions","volume":"22","author":"Maturu","year":"2015","journal-title":"J Bronchology Interv Pulmonol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3747\/co.22.2563","article-title":"Pleural Fluid Tumour Markers in Malignant Pleural Effusion with Inconclusive Cytologic Results","volume":"22","author":"Antonangelo","year":"2015","journal-title":"Curr Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.trsl.2015.04.006","article-title":"Diagnostic Value of Tumor Antigens in Malignant Pleural Effusion: a Meta-Analysis","volume":"166","author":"Nguyen","year":"2015","journal-title":"Translational Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000468545","article-title":"Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis","volume":"94","author":"Yang","year":"2017","journal-title":"Respiration"},{"key":"B10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3109\/00313021003631320","article-title":"Diagnostic Value of Her-2\/neu, Cyfra 21-1, and Carcinoembryonic Antigen Levels in Malignant Pleural Effusions of Lung Adenocarcinoma","volume":"42","author":"Huang","year":"2010","journal-title":"Pathology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/pat.0000000000000215","article-title":"Diagnostic Performance of CD66c in Lung Adenocarcinoma-Associated Malignant Pleural Effusion: Comparison with CEA, CA 19-9, and CYFRA 21-1","volume":"47","author":"Son","year":"2015","journal-title":"Pathology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10147-016-1073-y","article-title":"Diagnostic Value of Tumor Markers for Lung Adenocarcinoma-Associated Malignant Pleural Effusion: a Validation Study and Meta-Analysis","volume":"22","author":"Feng","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12931-020-01557-z","article-title":"Auxiliary Diagnostic Value of Tumor Biomarkers in Pleural Fluid for Lung Cancer-Associated Malignant Pleural Effusion","volume":"21","author":"Zhang","year":"2020","journal-title":"Respir Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1378\/chest.119.4.1138","article-title":"Diagnostic Value of CYFRA 21-1 Tumor Marker and CEA in Pleural Effusion Due to Mesothelioma","volume":"119","author":"Paganuzzi","year":"2001","journal-title":"Chest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0169-5002(03)00120-X","article-title":"Diagnostic Value of CA 549 in Pleural Fluid. Comparison with CEA, CA 15.3 and CA 72.4","volume":"40","author":"Villena","year":"2003","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.clinbiochem.2010.05.016","article-title":"Performance of CEA and CA19-9 in Identifying Pleural Effusions Caused by Specific Malignancies","volume":"43","author":"Hackbarth","year":"2010","journal-title":"Clin Biochem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12032-013-0543-6","article-title":"Diagnostic Value of Mesothelin in Pleural Fluids: Comparison with CYFRA 21-1 and CEA","volume":"30","author":"Filiberti","year":"2013","journal-title":"Med Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1378\/chest.126.6.1757","article-title":"Use of a Panel of Tumor Markers (Carcinoembryonic Antigen, Cancer Antigen 125, Carbohydrate Antigen 15-3, and Cytokeratin 19 Fragments) in Pleural Fluid for the Differential Diagnosis of Benign and Malignant Effusions","volume":"126","author":"Porcel","year":"2004","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1634\/theoncologist.10-7-501","article-title":"Diagnostic Value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 Assays in Pleural Effusions: Analysis of 116 Cases and Review of the Literature","volume":"10","author":"Shitrit","year":"2005","journal-title":"Oncologist"},{"key":"B20","first-page":"2947","article-title":"Clinical Utility of a Combination of Tumour Markers in the Diagnosis of Malignant Pleural Effusions","volume":"28","author":"Gaspar","year":"2008","journal-title":"Anticancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.21037\/jtd.2017.11.62","article-title":"Diagnostic Accuracy of Tumor Markers for Malignant Pleural Effusion: a Derivation and Validation Study","volume":"9","author":"Zhai","year":"2017","journal-title":"J Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"010706","DOI":"10.11613\/bm.2018.010706","article-title":"Diagnostic Value of Tumour Markers in Pleural Effusions","volume":"28","author":"Volari\u0107","year":"2018","journal-title":"Biochem Med (Zagreb)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","article-title":"Carcinoembryonic Antigen (CEA) as Tumor Marker in Lung Cancer","volume":"76","author":"Grunnet","year":"2012","journal-title":"Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.clinbiochem.2016.08.006","article-title":"Evaluation of Predictive Value of Pleural CEA in Patients with Pleural Effusions and Histological Findings: A Prospective Study and Literature Review","volume":"49","author":"Tozzoli","year":"2016","journal-title":"Clin Biochem"},{"key":"B25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1183\/09031936.93.02040366","article-title":"Pleural Metastatic Tumours and Effusions. Frequency and Pathogenic Mechanisms in a post-mortem Series","volume":"2","author":"Rodr\u00eeguez-Panadero","year":"1989","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/cam4.2809","article-title":"Analysis of Tumor Markers in Pleural Effusion and Serum to Verify the Correlations between Serum Tumor Markers and Tumor Size, TNM Stage of Lung Adenocarcinoma","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant Pleural Effusion: from Bench to Bedside","volume":"25","author":"Psallidas","year":"2016","journal-title":"Eur Respir Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/cncy.21283","article-title":"Diagnostic Value of Tumor Markers in Lung Adenocarcinoma-Associated Cytologically Negative Pleural Effusions","volume":"121","author":"Hsieh","year":"2013","journal-title":"Cancer Cytopathology"},{"key":"B29","first-page":"2383","article-title":"Diagnostic Accuracy of Cyfra 21-1 for Head and Neck Squamous Cell Carcinoma: a Meta-Analysis","volume":"17","author":"Wang","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1136\/thx.2010.136978","article-title":"Investigation of a Unilateral Pleural Effusion in Adults: British Thoracic Society Pleural Disease Guideline 2010","volume":"65","author":"Hooper","year":"2010","journal-title":"Thorax"},{"key":"B31","doi-asserted-by":"publisher","first-page":"775079","DOI":"10.3389\/fonc.2021.775079","article-title":"Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:48:08Z","timestamp":1675360088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":31,"alternative-id":["10.3389\/pore.2022.1610280"],"URL":"https:\/\/doi.org\/10.3389\/pore.2022.1610280","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"article-number":"1610280"}}